secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001159036-26-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme raises 2026 guidance; acquires Surf Bio for $300M upfront
------------------------------------------------------------------

- Preliminary 2025 revenue estimated at $1,385-1,400M (+36-38% YoY); royalties $865-870M (+51-52% YoY).
- 2026 revenue guidance raised to $1,710-1,810M (+23-30% YoY) from prior $1,430-1,530M; royalty revenue now >$1B.
- 2026 non-GAAP diluted EPS guidance raised to $7.75-8.25 (prior $6.50-7.00); Adjusted EBITDA $1,125-1,205M.
- Acquired Surf Bio for $300M upfront plus up to $100M milestones; adds hyperconcentration technology for biologics.
- Surf Bio technology enables 500 mg/mL antibody concentrations for single auto-injector subcutaneous delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000011/0001159036-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000011/halo-20260128.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer